# Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC

> **NCT01620944** · PHASE3 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 3 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** Atazanavir
- **DRUG:** Ritonavir
- **DRUG:** Lamivudine
- **DRUG:** Tenofovir/Emtricitabine

## Key facts

- **NCT ID:** NCT01620944
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-07-31
- **Primary completion:** 2013-01-22
- **Final completion:** 2013-01-22
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2024-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01620944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01620944, "Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01620944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*